US Dollar vs MXN

Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.

Regístrate

0RD1

Camurus Ab (0RD1)

Camurus Ab

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:LSE:0RD1

1

Fecha	Hora	Fuente	Título	Símbolo	Compañía
17/07/2023	00:40	PR Newswire (US)	Camurus announces new Phase 3 data reinforcing long-term safety and efficacy of octreotide SC depot (CAM2029) in patients with acromegaly	LSE:0RD1	Camurus Ab
23/05/2023	22:25	PR Newswire (US)	Camurus announces FDA approval of Brixadi™ for the treatment of moderate to severe opioid use disorder	LSE:0RD1	Camurus Ab
15/12/2021	16:15	PR Newswire (US)	Braeburn receives new Complete Response Letter for Brixadi in the US	LSE:0RD1	Camurus Ab
16/09/2021	04:38	PR Newswire (US)	FDA grants Orphan Drug Designation in the US for CAM2029 for the treatment of polycystic liver disease	LSE:0RD1	Camurus Ab
26/06/2021	11:09	PR Newswire (US)	Camurus announces PDUFA date for Brixadi for the treatment of opioid use disorder in the US	LSE:0RD1	Camurus Ab
15/06/2021	17:12	PR Newswire (US)	Camurus announces Braeburn resubmits New Drug Application for Brixadi™ in the US	LSE:0RD1	Camurus Ab
10/05/2021	10:22	PR Newswire (US)	Camurus announces publication showing superior patient treatment satisfaction with Buvidal® weekly and monthly depot injecti...	LSE:0RD1	Camurus Ab
03/05/2021	01:42	PR Newswire (US)	The Australian TGA approves key label updates to Buvidal® for treatment of opioid dependence	LSE:0RD1	Camurus Ab
26/03/2021	08:33	PR Newswire (US)	Camurus receives positive CHMP opinion for Buvidal 160mg monthly dose for the treatment of opioid dependence	LSE:0RD1	Camurus Ab
18/12/2020	01:27	PR Newswire (US)	Swissmedic approves Buvidal for the treatment of opioid dependence	LSE:0RD1	Camurus Ab
24/06/2020	07:38	PR Newswire (US)	Positive Results From Phase 2 Study of Once-weekly FluidCrystal® Formulation of Setmelanotide in Healthy Volunteers With Obe...	LSE:0RD1	Camurus Ab
23/06/2020	09:39	PR Newswire (US)	Camurus Raises Full Year 2020 Revenue Guidance	LSE:0RD1	Camurus Ab
01/06/2020	16:55	PR Newswire (US)	Camurus Announces Submission of Request for Final Approval of Brixadi™ for the Treatment of Opioid Use Disorder in the US	LSE:0RD1	Camurus Ab
14/05/2020	10:24	PR Newswire (US)	Camurus' Buvidal® Reimbursed in Sweden for the Treatment of Opioid Dependence	LSE:0RD1	Camurus Ab
07/05/2020	06:18	PR Newswire (US)	Camurus' Interim Report January-March 2020	LSE:0RD1	Camurus Ab
02/04/2020	01:37	PR Newswire (US)	Camurus Announces Strong First Quarter Demand for Buvidal®	LSE:0RD1	Camurus Ab
25/11/2019	20:59	PR Newswire (US)	Camurus Announces New Study Results Showing Superior Patient Reported Outcomes With Buvidal® Versus Standard of Care in Trea...	LSE:0RD1	Camurus Ab
07/11/2019	21:31	PR Newswire (US)	Camurus Announces That FDA Grants Braeburn's Citizen Petition, Eliminating the Risk of Further Blocking of Brixadi™ From th...	LSE:0RD1	Camurus Ab
26/08/2019	01:11	PR Newswire (US)	Camurus: Australian Minister for Health Announced PBS Listing of Buvidal® Weekly and Monthly for Treatment of Opioid Depende...	LSE:0RD1	Camurus Ab
23/07/2019	07:11	PR Newswire (US)	Camurus Announces Positive Outcome of U.S. Court Proceeding About Final Approval of Brixadi™	LSE:0RD1	Camurus Ab
16/07/2019	01:19	PR Newswire (US)	Ra Pharmaceuticals and Camurus Announce Exclusive License Agreement for FluidCrystal® Extended Release Formulation of Ziluco...	LSE:0RD1	Camurus Ab
20/06/2019	06:17	PR Newswire (US)	Camurus Receives IND Acceptance From the FDA to Enter Phase 3 with CAM2029 for Treatment of Acromegaly	LSE:0RD1	Camurus Ab
04/06/2019	02:38	PR Newswire (US)	Camurus Announces Publication of Phase 3 Study Results Showing Long-term Safety, Efficacy and High Rates of Patient Satisfact...	LSE:0RD1	Camurus Ab
09/05/2019	06:17	PR Newswire (US)	Camurus Interim Report January-March 2019	LSE:0RD1	Camurus Ab
28/11/2018	16:45	PR Newswire (US)	Buvidal® Weekly and Buvidal® Monthly (CAM2038) Approved in Australia as the First Long-acting Treatment of Opioid Dependenc...	LSE:0RD1	Camurus Ab
22/11/2018	05:15	PR Newswire (US)	Camurus Receives EU Approval for Weekly and Monthly Buvidal® (CAM2038) for Opioid Dependence	LSE:0RD1	Camurus Ab
21/09/2018	06:34	PR Newswire (US)	CHMP Recommends Approval of Buvidal® (CAM2038) for the Treatment of Opioid Dependence	LSE:0RD1	Camurus Ab

Showing the most relevant articles for your search:LSE:0RD1

1

US Dollar vs MXN

Invesco QQQ Trust Series 1

Deutsche Telekom (QX)

Financial Select Sector

American Express

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones